Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
COSTS AND EXPENSES:    
Research and development $ 6,654,094 $ 3,887,039
General and administrative 2,051,207 2,253,188
Total costs and expenses 8,705,301 6,140,227
LOSS FROM OPERATIONS (8,705,301) (6,140,227)
OTHER INCOME:    
Interest income, net 124,034 430
Total other income, net $ 124,034 430
NET LOSS   $ (6,139,797)
BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.76) $ (1.00)
DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.76) $ (1.00)
SHARES USED IN COMPUTING BASIC NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 11,261,217 6,110,125
SHARES USED IN COMPUTING DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 11,261,217 6,110,125